Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials

Table 4 Summary of forest plot for grade 3/4 TRAEs (Pem + B vs. B maintenance)

Grade 3/4 TRAEs	Pem + B n/N (%)	B n/N (%)	Heterogeneity I²	Heterogeneity P value	RR (95%CI)	P value
Anemia	35/620 (5.6%)	7/707 (1.0%)	41.8%	0.179	1.75 (1.46, 2.09)	0.000
Hypertension	97/620 (15.6%)	98/707 (13.9%)	60.8%	0.078	1.02 (0.78, 1.34)	0.864
Neutropenia	81/620 (13.1%)	6/707 (0.8%)	0%	0.872	1.95 (1.80, 2.12)	0.000
Thrombocytopenia	14/620 (2.3%)	1/707 (1.0%)	10.4%	0.291	1.88 (1.55, 2.28)	0.000

Abbreviation: Pem + B Pemetrexed and bevacizumab; B Bevacizumab; RR Risk ratio; TRAEs Treatment-related adverse events

ISSN: 1471-2407